Abstract
We describe seven patients who developed symptoms including severe headache, circumoral paresthesia, and facial flushing during high-dose carmustine (BCNU) infusion as part of the preparative regimen for autologous peripheral blood stem cell (PBSC) transplantation for metastatic breast cancer. Five patients responded to pain medications, including partial and complete opiate receptor agonists. Premedication of subsequent doses of BCNU with corticosteroids, pain medications, or benzodiazepines lessened, but did not prevent the same symptoms from recurring. The incidence and mechanism of this toxicity are unknown, but this adverse syndrome should be considered when administering high-dose BCNU infusions.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Woo, M., Ippoliti, C., Bruton, J. et al. Headache, circumoral paresthesia, and facial flushing associated with high-dose carmustine infusion. Bone Marrow Transplant 19, 845–847 (1997). https://doi.org/10.1038/sj.bmt.1700743
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1700743
Keywords
This article is cited by
-
Infusion reactions are common after high-dose carmustine in BEAM chemotherapy and are not reduced by lengthening the time of administration
Supportive Care in Cancer (2017)
-
Carmustine infusion reactions are more common with rapid administration
Supportive Care in Cancer (2012)